Regional comparisons of COVID reporting rates, burden, and mortality age-structure using auxiliary data sources

Mollie M. Van Gordon^{a,1}, Lawrence Mwananyanda^{b,c}, Christopher J. Gill^b, and Kevin A. McCarthy^a

^a Institute for Disease Modeling at the Bill & Melinda Gates Foundation; ^bDepartment of Global Health, Boston University School of Public Health; ^cRight To Care – Zambia

This manuscript was compiled on August 18, 2021

We correct common assumptions about COVID burden and disease characteristics in high-income (HIC) versus low- and middle-income 2 (LMIC) countries by augmenting widely-used surveillance data with 3 auxiliary data sources. We constructed an empirically-based model 4 of serological detection rates to quantify COVID reporting rates in 5 national and sub-national locations. From those reporting rates, we 6 estimated relative COVID burden, finding results that contrast with 7 estimates based on case counts and modeling. To investigate COVID 8 mortality by age in an LMIC context, we utilized a unique morgue 9 study of COVID in Lusaka alongside the population attributable frac-10 tion method to account for HIV comorbidity. We calculated the 11 comorbidity-corrected age-adjusted mortality curve in Lusaka and 12 found it significantly skewed toward younger age groups as com-13 pared to HICs. This unexpected result recommends against the un-14 examined use of HIC-derived parameterizations of COVID character-15 istics in LMIC settings, and challenges the hypothesis of an age-16 structure protective factor for COVID burden in Africa. Indeed, we 17 found overall COVID burden to be higher in Lusaka than in HICs. 18 Concurrent with high COVID burden, many LMICs have high preva-19 lence of other public health issues such as HIV, which compete 20 for limited health investment resources. Given differences in age-21 structure, comorbidities, and healthcare delivery costs, we provide a 22 case study comparing the cost efficacy of investment in COVID ver-23 sus HIV and found that even in a high HIV prevalence setting, invest-24 ment in COVID remains cost-effective. As a whole, these analyses 25 have broad implications for interpretations of COVID burden, model-26 ing applications, and policy decision-making. 27

COVID-19 | Surveillance | Reporting rates | Disease burden | Mortality age-structure

E ffective counter-measures against the raging COVID-19 pandemic require accurate geographically-specific knowl-1 2 3 edge, but surveillance and data inequities present major chal-4 lenges to these efforts. Surveillance systems are generally more robust in high-income countries (HICs), meaning that data 5 from HICs tend to be more readily available and complete 6 than data from low- and middle-income countries (LMICs) 7 (1, 2). For lack of locally-specific data, epidemiological charac-8 teristics of COVID are often based on data from HICs, but the 9 transferability to LMIC contexts remains an open question (3). 10 11 Accounting for differences in surveillance and incorporating auxiliary data sources can help fill these data gaps and inform 12 our understanding of COVID across contexts. 13

For example, official statistics on regional COVID burden are based on reported case counts (4), despite evidence of substantial case underreporting particularly in LMIC contexts (5, 6). Such differences in reporting rates can significantly alter estimates of relative disease burden across regions (7). COVID reporting rates are difficult to determine, but incorporating serological data can inform reporting rate estimates. While serology is challenging to work with, it offers some of the best information in data-sparse settings if the limitations of serological data are accounted for (8, 9).

Surveillance and reporting influence our understanding of 24 COVID dynamics in other ways as well. For example, while 25 there is strong evidence that COVID parameters such as infec-26 tion fatality rate (IFR) vary even within HICs, data challenges 27 in LMICs mean that HIC estimates are often used in LMIC 28 settings (10). This practice has major implications for esti-29 mates of COVID burden and risk factors, and subsequently for 30 policies and public health practices targeting COVID. The com-31 mon understanding of IFRs and the age-structure of COVID 32 mortality has led to hypotheses that Africa's young population 33 distributions have a protective effect against COVID (11), yet 34 questions remain about impacts of comorbidity distributions, 35 differences in disease characteristics across settings, and the 36 role of COVID interventions in the context of other public 37 health concerns. 38

We address these questions and assumptions through auxiliary data sources. Using serological modeling, we calculate reporting rates for different national and sub-national locations in HICs and LMICs. We then use that data in a reporting rate model to adjust national burden estimates accounting for differences in surveillance. Taking a closer look at a local 44

Significance Statement

The analyses presented here demonstrate the power of auxiliary COVID data sources to fill information gaps, particularly for LMICs. Our results reveal differences in COVID surveillance and disease dynamics between HICs and LMICs that challenge common perceptions and assumptions about COVID in these respective contexts. We show the divergence of COVID reporting rates between HICs and LMICs and the effects on relative estimated burden. Contradicting common modeling practices, our analysis demonstrates that the age-structure of COVID mortality cannot be accurately generalized from HICs to LMICs. We find higher COVID burden in LMIC contexts than HICs particularly in younger age groups and show that investment in COVID is cost-effective even in light of other public health concerns.

Author contributions are as follows. MVG: conceptualization, literature search, data curation, formal analysis, investigation, methodology, project administration, software, validation, visualization, writing of the original draft, review and editing. LM & CG: writing review and editing. KM: conceptualization, methodology, review and editing.

The authors declare no competing interests.

¹To whom correspondence should be addressed. E-mail: mvangordon@idmod.org

context, we use morgue sampling data to circumvent issues 45 introduced by sampling bias, and statistical approaches to 46 adjust for comorbidity. With this age-disaggregated data we 47 compare mortality age-structure and burden between LMIC 48 49 and HIC contexts. Cognizant of competing public health is-50 sues, particularly in LMIC contexts, we examine relative costs and benefits of investing in COVID vaccine. 51

In this article, we first present our results on reporting rates 52 across locations and relative regional COVID burden informed 53 by serology. Next, we use auxiliary data from Zambia to 54 examine mortality age-structure in an LMIC-specific location, 55 and conduct an impact comparison of COVID intervention 56 with other public health interventions. We follow with a 57 discussion describing broader implications of our study results 58 for programmatic and modeling applications. Finally, we 59 describe in detail our data and methods, including serological 60 and reporting rate modeling, mortality burden quantification, 61 statistical correction of COVID mortality for comorbidity 62 factors, and the cost modeling used to compare public health 63 investments. 64

Results 65

Serology across World Health Organization (WHO) regions. 66

Reporting rates in the European region and the region of the Amer-67 icas (EURO and AMRO) are higher than elsewhere. Matching sero-68 prevalence estimates with reported cases in a particular lo-69 cation allows calculation and comparison of reporting rates 70 71 (Figure 1). We take the cumulative reported cases for a location, up until the time of the serostudy, and adjust the case 72 rate by a model of seroconversion and reversion. This case 73 rate is lower than the raw reported cumulative case rate, as 74 serosurveillance does not detect all infections. Reporting rates 75 follow the dashed gray lines on the plot. In general, countries 76 77 in the AMRO and EURO regions have the highest reporting rates, shown on a log scale. Note that seroprevalence cannot be 78 directly compared across locations because of the differences 79 in the dates of the serostudies. 80

Because serostudy data from the African region (AFRO) 81 are sparse, we include sub-national prevalence estimates, and 82 match those with case data from the particular sub-national 83 locations only. Kenya and Zambia have data for multiple 84 sub-national locations, and in both countries reporting rates 85 vary by more than a factor of ten. While there is a clear 86 correlation between seroprevalence and reported cases, there 87 are notable exceptions that appear to align with national 88 wealth. For example, Niger State and Cape Town both have 89 similar seroprevalence rates, but differ a thousand-fold in 90 reported cases. South Africa is a country with considerable 91 resources, expertise, and infrastructure for disease surveillance, 92 and there is reason to expect that capacity to test and report 93 COVID cases is likely better in Cape Town than across Niger 94 State. A similar argument can be hypothesized for other low 95 income countries on this matrix. 96

Ranked estimated infections show lowest burden in EURO. To iden-97 tify the location-specific effects of reporting rates on reported 98 case burden, we estimated infection burden across locations on 99 the same date. Serostudies provide estimates of reporting rates 100 for a specific window of time, but we don't assume reporting 101 rates are constant in time. To address this challenge, we used 102 our point estimates of reporting rates to build an model for 103



Fig. 1. Adjusted reported cases vs. crude seroprevalence by location. Dashed gray lines indicate reporting rates, labeled on the inside of the y-axis. WHO region is shown in color; sub-national locations in Kenya and Zambia are indicated with symbols.

the relationship between reporting rate and testing rate, for which we have continuous time series data. We then used the testing rate time series to model dynamic reporting rates and unify the dates of estimated infections.

Figure 2 shows a ranking of COVID burden across locations 108 on November 12th, 2020, the most recent date with continuous available testing data for all locations. The top plot shows the ranking based on reported cases; the bottom plot shows the ranking of estimated infections calculated using reporting rates. In the reported case burden ranking, the EURO region is high relative to other regions; however in the estimated infections ranking, EURO countries have low burden relative to other regions.

We note that increased estimated cases relative to reported cases occurs mainly, but not exclusively, in lower resource country settings. As with the analysis presented in Figure 1, these data support the concern that underreporting, perhaps as a consequence of resource limitations, may lead to a significant under-counting of cases in certain parts of the world.



Fig. 2. Ranking of cumulative COVID reported cases (top) and estimated infections (bottom) as of November 12th, 2020.

121

122

104

105

106

107

123 COVID mortality in Lusaka.

COVID mortality burden is substantial among younger age groups in 124 Lusaka and higher overall as compared to HICs. Based on a morgue 125 study in Lusaka, Figure 3, top left, shows the percentage of 126 all-cause deaths that tested positive for COVID postmortem, 127 adjusted to exclude HIV-attributable comorbid deaths. The 128 frequency of COVID deaths by a ge-bin hovers between 9% and 129 19% for all age groups up to age 70. COVID death frequencies 130 in the 70s and 80+ age bins are 24% and 34%, respectively. 131 Using age structures of population and life expectancy, COVID 132 mortality frequencies can be translated into years of life lost 133 (YLL) by age group, which we present for Lusaka alongside 134 the United States for a comparison of LMIC and HIC contexts 135 (Figure 3, top right). While as expected, YLL per capita due 136 to COVID is highest in older age groups in the US, the pattern 137 in Lusaka is drastically different: young age groups, instead 138 of older age groups, suffer the highest COVID burden. In 139 addition, total years of life lost per capita across all age-bins 140 is higher overall in Lusaka than in the United States. 141

Plotted in Figure 3, bottom right, are age-adjusted COVID 142 mortality rates in Lusaka vs. HICs (log scale). In all age-143 groups, age-adjusted COVID mortality rates are higher in 144 Lusaka than in HICs. Fitting an exponential model to each 145 age-adjusted mortality curve provides an estimate of the rate 146 of increase of mortality with age. The slope of this model 147 is defined as the growth constant of the curve, plotted for 148 multiple locations in Figure 3, bottom left. The significantly 149 lower growth rate of mortality with age in Lusaka indicates 150 age-adjusted mortality is skewed toward higher mortality in 151 younger age groups as compared to HICs. While Lusaka is not 152 necessarily representative of all LMICs, these results highlight 153 the pitfall of generalizing COVID disease parameters from 154 HIC to LMIC contexts. 155

156 Costing mortality reduction.

Investment in COVID mortality reduction should be prioritized even 157 in the context of other public health challenges. Building on the 158 age-specific mortality dataset from Lusaka, we used basic cost 159 160 modeling to demonstrate the utility of investment in COVID mortality reduction. As HIV is the number one cause of death 161 in Zambia, we examine HIV investment alongside COVID 162 (12). We include for comparison the United States, a low HIV-163 burden HIC setting. Based on the age structures of population 164 as well as COVID and HIV mortality, we calculate total YLL 165 per capita for different levels of combined mortality reduction 166 167 of COVID and HIV across age groups. The heat maps in Figure 4 show these results for Zambia (left) and the United 168 States (right). Model input data are detailed in the table in 169 Figure 4. Costing model results are shown as white isotropic 170 lines on the heat maps, indicating cost per percent mortality 171 reduction for COVID and HIV combined. 172

In both Zambia and the United States, the cost of HIV 173 mortality reduction outstrips that of COVID mortality reduc-174 tion. As a result, the gradients across the cost model isotropic 175 lines are dominated by HIV mortality reduction in both plots. 176 The underlying structure of YLL per capita, however, differs 177 between the two countries. In the United States, the mag-178 nitude of COVID-attributed YLL per capita is twice that of 179 HIV-attributed YLL per capita, as annotated by the white 180 circles on the right plot. As a result, the gradient direction 181

The overlay of the cost/percent mortality reduction 189 isotropic lines and the YLL per capita heat map indicate the 190 cost efficacy of investment in HIV vs. investment in COVID. 191 In both the United States and Zambia on a constant per capita 192 budget, maximizing investment in COVID mortality reduction 193 relative to HIV investment minimizes YLL per capita, the 194 desired outcome. Note that there are many components to 195 decision-making about public health investment, and we do not 196 claim that our model results establish exact cost for mortality 197 reduction or that COVID investment is definitively indicated. 198 Rather, this analysis serves to unseat any a priori assumptions 199 that COVID burden is insignificant in settings with other 200 high-burden public health issues. Rather, COVID investment 201 should be considered as a possible avenue for cost-effective 202 reduction in total disease burden. 203

Discussion

Using surveillance data auxiliary to reported COVID cases 205 and deaths, we demonstrate that common assumptions about 206 regional COVID burden must be reconsidered. We calculate 207 reporting rates across locations and show the impact of regional 208 differences on perceived COVID burden. Further, contrary 209 to impressions derived from case counts, we establish higher 210 burden of COVID in the African context as compared to 211 HICs, particularly in younger age groups. This challenges 212 predominant assumptions about the age structure of mortality 213 rates and the protective effects of younger populations in 214 Africa (3, 8, 13). 215

204

Combining seroprevalence data with seroconversion and 216 reversion modeling, we calculate reporting rates across WHO 217 regions and present estimated infections across locations. Our 218 analysis shows high reporting rates in EURO and AMRO 219 relative to other regions, a data-based result consistent with 220 anecdotal understanding (1, 7). Heterogeneity of reporting 221 rates at the sub-national level adds to the common under-222 standing of geographic heterogeneity of COVID prevalence 223 (14, 15). By identifying a relationship between reporting rate 224 and testing rate, we unify the date of COVID prevalence es-225 timates and rank countries according to relative estimated 226 prevalence. The relatively low burden in EURO countries 227 contradicts geographic burden distributions based on reported 228 cases as well as modeling estimates (13, 16). 229

Randomly sampled morgue-based COVID testing data pro-230 vides the opportunity to evaluate mortality dynamics in an 231 African context, without the challenges associated with report-232 ing systems. The age structure of mortality in the African 233 setting is significantly different from HIC settings, with unex-234 pectedly higher burden in younger age groups. In addition, 235 overall mortality burden in the African setting outstrips that 236 in HICs. This poses serious risks for LMIC countries where 237 age distributions are skewed younger, directly contradicting 238 the age-protection hypothesis. We use the mortality data 239 alongside a simple cost model to show that even in a context 240 with substantial other public health concerns such as HIV, 241



Fig. 3. COVID mortality for Lusaka and HICs. Upper left: Frequency of COVID-positive deaths among all-cause deaths by age bin (Lusaka). Upper right: Years of life lost per capita by age bin for Lusaka and the United States. Lower right: Age-adjusted mortality for Lusaka and HICs by age bin. Lower left: Exponential rate of increase of age-adjusted mortality with age across locations. All mortality data is from early August, 2020. COVID mortality in Lusaka is adjusted to exclude HIV-attributable comorbid deaths. Shading and error bars represent 95% confidence intervals.



Fig. 4. Cost models of reduction of COVID and HIV mortality for Zambia (left) and the United States (right). Axes indicate model inputs of percent mortality reduction for HIV and COVID. Heat map illustrates remaining YLL/total population for HIV and COVID combined. Cost per capita for combined HIV and COVID mortality reduction are shown in white isotropic lines, labeled on the right y-axis of each plot. White circles on the plot are annotated with the total YLL per capita for one disease only, as indicated. Table shows model inputs for COVID and HIV cost per percent mortality reduction, sources cited in the Materials and Methods section.

COVID may be a cost-effective investment for disease burden 242 reduction. 243

Our study is subject to a number of limitations, particularly 244 as we grapple with understanding COVID dynamics in LMIC 245 contexts. LMICs are subject to limited data availability and 246 substantial uncertainty, which we address in part by making 247 use of sub-national data sources including serology and COVID 248 testing from morgue sampling. Challenges when working 249 with serology include inconsistencies in testing protocols and 250 sampling frameworks alongside the impacts of seroconversion 251 and reversion on results. To address these hurdles, we focus 252 on serostudies that do not target particular populations, and 253 adjust estimates for seroconversion and reversion. 254

Necessitated by data and uncertainty limitations, some of 255 the models we present rely on broad approximations. Modeling 256 reporting rate as a function of testing rate, for example, is an 257 approximation made to include countries where more detailed 258 auxiliary data are not available. We do not attempt to estimate 259 the magnitude of COVID burden in different locations, only 260 their relative ranking. Finally, cost modeling is presented as 261 a ballpark framework to evaluate COVID in the context of 262 other public health concerns, rather than a comprehensive 263 costing model. We use HIV as an example to compare with 264 COVID, recognizing that there are other sources of burden 265 and other approaches to public health investment than single 266 disease-focused strategies. We do not attempt to model the 267 complexities of mortality reduction dynamics, rather seeking 268 to demonstrate that COVID should be considered as part of a 269 public health investment portfolio. 270

The substantial differences in reporting rates across lo- 271

cations and the subsequent influence on perceived burden 272 highlight the pitfalls of making programmatic decisions based 273 on reported cases alone. The differences in mortality and bur-274 den between Africa and HIC contexts calls for caution when 275 276 translating epidemiological age structure assumptions from 277 HIC to LMIC contexts, and rethinking assumptions about protective factors for perceived lower burden in African contexts. 278 Cost-effectiveness of COVID mortality reduction recommends 279 investment even in contexts with other entrenched public 280

health concerns and limited vaccine efficacy.

282 Materials and Methods

Data. Reporting rate analysis relies on serostudies and reported 283 cases. In order to reduce bias in the serology data, only studies 284 that do not target a particular population (e.g. health care 285 workers) were included. For WHO regions other than AFRO, 286 nationally pooled seroprevalence estimates were used (2, 17). 287 Because serostudy data in AFRO are sparse, both national 288 estimates and sub-national estimates were included (14, 18-289 22). National case rates were obtained from Our World in Data 290 (16). Sub-national case rates were calculated from sub-national 291 reported case counts and population data (14, 15, 19, 23–31). 292 293 Because vital reporting systems in Africa can be limited (32), we used a morgue sampling study for COVID and HIV 294 mortality rates in Lusaka instead of reported numbers (6), all-295 cause mortality rate for Lusaka (32), and HIV prevalence data 296 for Zambia (33). Zambia HIV prevalence data was extrapo-297 lated to older age bins corresponding to other data sources via 298 a Gaussian model. For HICs, where vital reporting systems 299 are strong, reported age-binned mortality rates for COVID 300 and HIV were used (34, 35). Years of life lost and age-adjusted 301 mortality require life expectancy and population by age, which 302 were pulled from the UN World Population Prospects and the 303 2018 Zambia Demographic and Health Survey (36, 37). Input 304 data for cost models included vaccine delivery, cost and efficacy 305 for COVID, and an established costing model for HIV (38-42). 306 Cost data from the literature were adjusted for inflation to 307 2021 dollars. 308

309 Methods.

Seroconversion and reversion. Seropositivity provides an indica-310 tor of the number of past infections, which can be compared 311 with cumulative reported cases to estimate reporting rate. 312 313 The probability of testing seropositive, however, is a function 314 of the elapsed time from infection because of seroconversion 315 and reversion dynamics. In other words, a serostudy does not detect all past infections. For a fair comparison of detected 316 seropositivity with reported cases, we adjusted reported cases 317 down to the number of those cases that could be detected by 318 serosampling based on a model of seroconversion and reversion. 319 We tested two models for calculating this case adjustment, 320 each with different data requirements. 321

The more data-intensive model requires continuous time 322 series of daily reported case data. The model provides an 323 estimate of the probability for an infection to appear seroposi-324 tive at time t, where t is the time between infection and the 325 serostudy. To construct this model, we combined empirical 326 models for the probabilities of seroconversion (43) and rever-327 sion (44), Figure S1. Where τ is the time between infection and 328 seroconversion, conv indicates seroconversion, rev indicates 329

seroreversion, P(t) indicates the probability of seroconversion or reversion at time t, and p(t) indicates the probability of seroconversion or reversion by time t, the probability of an infection being seropositive at time t is as follows:

$$P_{pos}(t) = p_{conv}(t) - \int_0^t P_{conv}(\tau) p_{rev}(t-\tau) d\tau$$
³³⁴

Because the empirical models from the literature include only about four months of data, we used the last month of the combined empirical model to extrapolate out to a year using a log-linear regression. The full P_{pos} model is shown in Figure S2.

The calculation for a point estimate of reporting rate using this model of seropositivity is then as follows, where T_k is the date the serostudy k was conducted, R is reporting rate, c is daily reported cases, and S is seropositivity rate: 340

$$R_{T_k} = \frac{\int_0^{T_k} c(t) * P_{pos}(t) dt}{S_{T_k}}$$
 344

While continuous daily case reporting data largely exists 345 for HICs, LMICs do not necessarily report data at a daily 346 frequency, particularly for sub-national locations. In order 347 to be able to include more LMIC serology studies, we also 348 developed a less data-intensive model for the case count adjust-349 ment to approximate seroconversion and reversion dynamics. 350 In this model, only two data points for cumulative cases are 351 required: cumulative cases at 21 days and 60 days before the 352 serostudy. These time delays were selected heuristically to 353 account for seroconversion and reversion, respectively. Only 354 cases reported within these time bounds are then used for the 355 reporting estimation. Where C is cumulative cases: 356

$$R_{T_k} = \frac{C_{(T_k - 21days)} - C_{(T_k - 60days)}}{S_{T_k}}$$
357

We compared results from the two different models for adjusting cases and estimating reporting rate. We found the less data-intensive model to be a good approximation of the more complete probability-based model, see Figure S3. We used the second, less data-intensive model for Figure 1 to include sub-national locations, and the probability-based model for Figure 2.

Dynamic reporting rate modeling. With reporting rate estimates 365 based on serostudies each conducted at a different time T_k , it 366 remains to unify dates of estimated infection rates for com-367 parison across locations. To allow reporting rates to vary over 368 time, we constructed a hybrid reporting rate model based on 369 the reporting rate at the time of a serostudy and the log-log 370 relationship between testing rate and reporting rate in the 371 serostudy locations. 372

As the serostudies we used are relatively early in the pan-373 demic, we approximated reporting rate up until the time of 374 a serostudy as the reporting rate at the time of the seros-375 tudy. This offsets under-estimation of reporting rates early in 376 the pandemic when testing policies were largely symptomatic 377 and testing rates were low. For dates after the serostudy, 378 we allowed the reporting rate to vary with testing rate. The 379 parameters of the relationship between these two variables 380 were established by a log-log regression, illustrated in Figure 381

S4. Where α and β are parameters of the regression fit and E 382 is testing rate: 383

$$log(R_{T_k}) = \alpha + \beta(log(E_{T_k}))$$

Figure S5 illustrates output from the hybrid reporting rate 385 model for a few example countries. The modeled reporting 386 rate over time was then used to calculate cumulative estimated 387 infections per capita at time T: 388

389
$$I(T) = \int_0^{T_k} \frac{c(t)}{R_{T_k}} dt + \int_{T_k}^T \frac{c(t)}{e^{\alpha} E(t)^{\beta}} dt$$

Mortality and years of life lost. Formulations for mortality and 390 years of life lost in Lusaka were determined by available data. 391 Despite the challenges that the number of deaths in Lusaka at 392 large is difficult to determine and the catchment of the Lusaka 393 morgue study is unknown, the randomly sampled morgue 394 data made it possible to create formulations for age-adjusted 395 mortality and YLL that use only available information. 396

By definition, where pop(age) is population by age bin; Pop397 is total population; deaths(age) is deaths by age bin; Deaths398 is total deaths; and e(age) is life expectancy by age: 399

Age-adjusted mortality =
$$\frac{deaths(age)}{pop(age)}$$

$$YLL(age) = deaths(age) * e(age)$$

Where morgue(age) indicates the number of deaths by 403 age bin from the morgue sample, $Morgue_{AC}$ indicates the 404 total all-cause deaths in the morgue sample, and $Deaths_{AC}$ 405 indicates the total all-cause deaths in Lusaka, we approximated 406 $\frac{deaths(age)}{Deaths_{AC}} as \frac{morgue(age)}{Morgue_{AC}}.$ We used the crude death rate for Lusaka from (32): $\frac{Deaths_{AC}}{Pop} = \frac{12.2}{1000}.$ For $\frac{pop(age)}{Pop}$, we used the urban population distribution from (37). Age-adjusted 407 408 409 mortality then becomes: 410

$$\frac{deaths(age)}{pop(age)} = \frac{deaths(age)}{Deaths_{AC}} * \frac{Deaths_{AC}}{Pop} * \frac{Pop}{pop(age)}$$

YLL is calculated per capita: 412

$$\frac{YLL}{Pop} = \sum_{age} \frac{deaths(age)}{Deaths_{AC}} * \frac{Deaths_{AC}}{Pop} * e(age)$$

See Figure S6 for a breakdown of the frequencies of COVID 414 and HIV within age-binned deaths. The methodology for the 415 calculations of the increase of mortality rates with age are 416 based on Goldstein & Lee (45). 417

Population attributable fraction. For deaths that are both 418 COVID+ and HIV+, we attributed some to COVID and 419 some to HIV based on the population attributable fraction 420 method (46). Where $deaths_{(COV+)}$ denotes all COVID+ 421 deaths, $deaths_{(COV+|HIV+)}$ denotes COVID+ deaths that were 422 also HIV+, $deaths_{(COV+|HIV-)}$ denotes COVID+ deaths with a 423 negative or undetermined HIV status, and HIV indicates HIV 424 prevalence, the population attributable fraction, calculated by 425 age bin, is formulated as follows: 426

$$_{427} PAF = \frac{deaths_{(COV+|HIV+)}}{deaths_{(COV+)}} - \left(\frac{deaths_{(COV+|HIV-)}}{deaths_{(COV+)}} * \frac{HIV}{1 - HIV}\right)$$

And deaths attributed to COVID by age bin are as follows: 428

$$deaths_{COVattr} = deaths_{(COV+)}(1 - PAF)$$

Cost modeling. Cost per percent mortality reduction for COVID 430 was formulated as follows: 431

$$cost_{(COV)} = (delivery_{vax} + cost_{vax}) * \frac{0.01}{efficacy_{vax}}$$
432

Existing literature informed vaccine delivery cost estimates 433 (38). Vaccine cost and efficacy was calculated for the United 434 States based on mRNA vaccines against wild type COVID 435 (39, 40). For Zambia, vaccine cost and efficacy was calculated 436 based on AstraZeneca against variant B1.351 (39, 41). Cost 437 per percent mortality reduction for HIV came directly from 438 the literature (42). 439

ACKNOWLEDGMENTS. We gratefully acknowledge the team 440 responsible for the collection and processing of the morgue data 441 from Zambia, namely, William MacLeod, Geoffrey Kwenda, Rachel 442 Pieciak, Zachariah Mupila, Rotem Lapidot, Francis Mupeta, Leah 443 Forman, Luunga Ziko, Lauren Etter, and Donald Thea (6). Thanks 444 also to Mandy Izzo for her editorial support. 445

YA Adebisi, et al., SARS-CoV-2 diagnostic testing in Africa: Needs and challenges. Pan Afr Med J 35 (2020)

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

- A Rostami, et al., SARS-CoV-2 seroprevalence worldwide: A systematic review and meta analysis. Clin. Microbiol. Infect. 0 (2020)
- BL Rice, et al., Variation in SARS-CoV-2 outbreaks across sub-Saharan Africa. Nat Med 27 (2021)
- 4 WHO, COVID-19 Weekly Epidemiological Update, 15 Dec 2020, (World Health Organization), Technical report (2020).
- NK Ibrahim, Epidemiologic surveillance for controlling Covid-19 pandemic: Types, challenges and implications. J. Infect. Public Heal. 13 (2020).
- L Mwananyanda, et al., Covid-19 deaths in Africa: Prospective systematic postmortem 6. surveillance study. BMJ 372 (2021).
- F Kobia, J Gitaka, COVID-19: Are Africa's diagnostic challenges blunting response effective-7. ness? AAS Open Res 3 (2020).
- 8. JM Maeda, JN Nkengasong, The puzzle of the COVID-19 pandemic in Africa. Science 371 (2021).
- AN Ndaye, et al., Challenges in interpreting SARS-CoV-2 serological results in African coun-9. tries. The Lancet Glob. Heal. 9 (2021).
- 10. AT Levin, et al., Assessing the age specificity of infection fatality rates for COVID-19: Systematic review, meta-analysis, and public policy implications. Eur J Epidemiol 35 (2020).
- 11. D Ghosh, JA Bernstein, TB Mersha, COVID-19 pandemic: The African paradox, J Glob Heal 10 (2020)
- 12 WHO - Global Health Observatory, Global health estimates: Leading causes of death (2021). MRC Centre for Global Infectious Disease Analysis, Imperial College London, Imperial Col-13.
- lege COVID-19 LMIC Reports, Technical report (2020). 14. LB Mulenga, et al., Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020; A
- cross-sectional cluster sample survey. The Lancet Glob. Heal. 0 (2021). 15 WC Government, Western Cape Covid-19 Dashboard | Covid-19 Response (2021).
- 16. M Roser, H Ritchie, E Ortiz-Ospina, J Hasell, Coronavirus Pandemic (COVID-19), (Our World in Data), Technical report (2020).
- MV Murhekar, et al., Prevalence of SARS-CoV-2 infection in India: Findings from the national 17. serosurvey, May-June 2020. Indian J. Med. Res. 152 (2020).
- BN Alemu, et al., Sero-prevalence of anti-SARS-CoV-2 Antibodies in Addis Ababa, Ethiopia. 18. bioRxiv 0 (2020)
- 19. AL Batchi-Bouyou, et al., High SARS-CoV-2 IgG/IGM seroprevalence in asymptomatic Congolese in Brazzaville, the Republic of Congo. Int. J. Infect. Dis. 106 (2021).
- 20 M Hsiao et al. SARS-COV-2 SEROPREVALENCE IN THE CAPE TOWN METROPOLITAN SUB-DISTRICTS AFTER THE PEAK OF INFECTIONS, (National Institute for Communicable Diseases), Supplemental Issue 5 Volume 18 (2020).
- 21. H Majiya, et al., Seroprevalence of COVID-19 in Niger State. medRxiv 0 (2020)
- S Uyoga, et al., Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. 22. Science 371 (2021)
- 23. M Kagwe, COVID-19 Pandemic Situation Update as at 1/05/2020 - Kenya, (Kenya Ministry of Health), Technical report (2020)
- Kenya Ministry of Health, COVID-19 Outbreak in Kenya, Daily Situation Report 132, Techni-24 cal report (2020) 25
- Ministre de la Sante Congo, SITREP COVID-19 Nº111 du 16 Novembre 2020, Technical report (2020)
- 26. Nigeria Cetre for Disease Control, Confirmed COVID19 Cases - Nigeria 2021 (2021). Nigeria National Bureau of Statistics, Demographic Statistics Bulletin 2017, Technical report 27.
- (2018)
- SS Africa, Provinces at a Glance: Community Survey 2016, Technical report (2016).
- 29 ZNPH Institute, Zambia Situation Report No. 59, Technical report (2020).
- 30 ZNPH Institute, Zambia Situation Report No. 69, Technical report (2020)
- 31. ZNPH Institute, Zambia Situation Report No. 75, Technical report (2020). SS Mudenda, et al., Feasibility of using a World Health Organization-standard methodology
- 501 for Sample Vital Registration with Verbal Autopsy (SAVVY) to report leading causes of death 502 in Zambia: Results of a pilot in four provinces, 2010, Popul Heal, Metr 9 (2011) 503
- 33. Ministry of Health, Zambia, Zambia Population-based HIV Impact Assess ment (ZAMPHIA) 504 2016: Final Report, (Lusaka, Ministry of Health), Technical report (2019) 505

401

402

41

- 506 34. Institut national d'études démographiques, Data & metadata (2021).
- Sono 235. Centers for Disease Control and Prevention, HIV Surveillance Report 2018 (updated), Technical report (2020).
- United Nations Department of Economic and Social Affairs, World Population Prospects Population Division United Nations (2019).
- 37. ZSA Zsa, MoH Moh, UTHVL Uth-VI, ICF, Zambia Demographic and Health Survey 2018, Technical report (2020).
- 38. A Portnoy, et al., Costs of vaccine programs across 94 low- and middle-income countries.
 Vaccine 33 (2015).
- 515 39. UNICEF, COVID-19 Vaccine Market Dashboard (2020).
- SA Madhi, et al., Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351
 Variant. *N. Engl. J. Med.* 0 (2021).
- FP Polack, et al., Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 383 (2020).
- E Lamontagne, M Over, J Stover, The economic returns of ending the AIDS epidemic as a public health threat. *Heal. Policy* **123** (2019).
- AS Iyer, et al., Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. *Sci. Immunol.* 5 (2020).
- D Herrington, TCCRPS Group, Duration of SARS-CoV-2 Sero-Positivity in a Large Longitudinal Sero-Surveillance Cohort: The COVID-19 Community Research Partnership. *medRxiv* 0 (2021).
- JR Goldstein, RD Lee, Demographic perspectives on the mortality of COVID-19 and other
 epidemics. *PNAS* 117 (2020).
- 46. SA Western Cape Department of Health, National Institute for Communicable Diseases, Risk
 Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from
 the Western Cape Province, South Africa. *Clin. Infect. Dis.* 0 (2020).